Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2024 03:00 ET | Source: Curium

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer

first doses of PYLCLARI in France for prostate cancer patients
May 30, 2024 03:00 ET | Source: Curium US LLC

Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate

PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
May 29, 2024 03:32 ET | Source: Curium

Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year

PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
May 06, 2024 04:25 ET | Source: Curium

Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
May 06, 2024 04:25 ET | Source: Curium

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
April 23, 2024 00:01 ET | Source: Curium

Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials

patient enrollment in clinical trial
April 09, 2024 08:50 ET | Source: Curium

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE
April 09, 2024 04:13 ET | Source: Curium US LLC

핵의학 기업 Curium, Eczacibaşi-Monrol 인수 통해 Lutetium-177 생산능력 강화와 PET 입지 확대 전망

Eczacıbaşı-Monrol 인수 제안에 대한 내용은 다음과 같다: 이미 진행되고 있는 기존의 Lu-177 파트너십에 기반해 동위원소 제조분야의 선도적인 기업을 구축한다.현재 Curium이 진출하지 않은 지역을 대상으로 12개의 PET 사이트를 Curum의 기존 네트워크에 포함시킨다.Curium은 SPECT 제조 역량과 광범위한 물류 인프라를 추가로...
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium 计划通过收购 Eczacibaşi-Monrol 的协议大幅扩大镥-177 产能及 PET 业务范围

此项拟议的 Eczacıbaşı-Monrol 收购将：在现有的镥-177 合作伙伴关系基础上，创立领先的同位素制造商在 Curium 目前没有业务的地区为其现有网络增加 12 个 PET 站点为 Curium 增加 SPECT 生产能力和广泛的物流基础设施提高诊断和治疗方案的可靠性，从而造福患者巴黎, April 09, 2024 (GLOBE NEWSWIRE) --...
April 09, 2024 04:13 ET | Source: Curium

Curium plant mit der Vereinbarung zur Übernahme von Eczacıbaşı-Monrol eine erhebliche Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im PET-Bereich

Die geplante Übernahme von Eczacıbaşı-Monrol soll Folgendes erreichen: Ausbau der bestehenden Partnerschaft im Bereich Lu-177, um führender Hersteller des Isotops zu werdenErweiterung des bestehenden...